Literature DB >> 8678956

Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: is parathyroid transplantation indicated?

R A Decker1, J D Geiger, C E Cox, M Mackovjak, M Sarkar, M L Peacock.   

Abstract

Identification of germline mutations in the RET proto-oncogene predisposing to multiple endocrine neoplasia type IIa (MEN-IIa) has allowed a DNA-based approach to diagnosis and treatment by prophylactic thyroidectomy in children testing genetically positive. Although total thyroidectomy is the accepted operation for C cell disease, the necessity of routine total parathyroidectomy and autotransplantation as previously described in these asymptomatic children is questionable, particularly given the low occurrence of hyperparathyroidism in MEN-IIa (10-20%). Thirty-six children (ages 1 month to 12 years) from four MEN-IIa kindreds at risk for disease underwent genetic testing. Mutational analysis was done using a highly sensitive PCR-based denaturing gradient gel electrophoresis technique. Parathyroid or serum calcium concentrations were determined preoperatively. Of the 36 children at risk, 18 were found to have a MEN-IIa mutation; 11 have undergone prophylactic thyroidectomy at ages ranging from 2 to 12 years (mean 7.5 years). In each case, there was no biochemical evidence of hypercalcemia preoperatively, and all parathyroid glands were identified and were found to be grossly normal at exploration. Glands were carefully dissected and left in situ. Postoperatively, 10 of the 11 children maintained normocalcemia, allowing discharge within 24 to 36 hours. Resected thyroid glands contained C cell hyperplasia in nine, medullary carcinoma in one, and normal histology in one. We conclude that an alternative to routine parathyroidectomy may be desirable for prophylactic treatment of MEN-IIa. In situ parathyroid preservation can be safely achieved without compromising the completeness of the thyroid resection. This conservative approach obviates the potential morbidity associated with total parathyroidectomy and autotransplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8678956     DOI: 10.1007/s002689900124

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  9 in total

1.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

Review 2.  Endocrine tumor syndromes in infancy and childhood.

Authors:  Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

Review 3.  Bilateral neck exploration in primary hyperparathyroidism--when is it selected and how is it performed?

Authors:  Jacob Moalem; Marlon Guerrero; Electron Kebebew
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

4.  Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2.

Authors:  Jeffrey F Moley; Michael Skinner; William E Gillanders; Terry C Lairmore; Kathryn J Rowland; Amber L Traugott; Linda X Jin; Samuel A Wells
Journal:  Ann Surg       Date:  2015-10       Impact factor: 12.969

Review 5.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

6.  Surgical approach to the patient with familial hyperparathyroidism.

Authors:  Lindi H VanderWalde; Philip I Haigh
Journal:  Curr Treat Options Oncol       Date:  2006-07

7.  Pediatric ethics guidelines for hereditary medullary thyroid cancer.

Authors:  M Sara Rosenthal; Douglas S Diekema
Journal:  Int J Pediatr Endocrinol       Date:  2011-03-07

8.  An introduction to managing medullary thyroid cancer.

Authors:  Jan Willem de Groot; Thera P Links; Robert Mw Hofstra; John Tm Plukker
Journal:  Hered Cancer Clin Pract       Date:  2006-07-15       Impact factor: 2.857

9.  Medullary thyroid carcinoma.

Authors:  Jeffrey F Moley
Journal:  Curr Treat Options Oncol       Date:  2003-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.